Medtronic Appoints Ingrid Goldberg as New VP of Investor Relations, Formerly of Johnson & Johnson Subsidiary Abiomed

Source: Medical Device Business Review

January 2025On February 8, Medtronic announced an important personnel appointment:Ms. Ingrid Goldberg officially joined the company as Vice President and Head of Investor Relations.This appointment is related to the company's diabetes business unit.(Being spun off into an independent MiniMed company)The strategic adjustment is carried out simultaneously.

Ryan Weispfenning (Left) to Step Down and Lead Investor Relations for Medtronic's MiniMed Company

Ingrid Goldberg (Right) Medtronic's New Head of Investor Relations

Ms. Goldberg officially joined Medtronic today, bringing with her over 20 years of industry experience.Professional experience covers fields such as finance, medical devices, and life sciences.

Goldberg recently served as the Vice President of Finance and Investor Relations at Novocure, responsible for investor relations, communications, and business development.Before joining Novocure, she held several leadership positions at Abiomed (now part of Johnson & Johnson MedTech).

Medtronic stated,Goldberg led the investor relations department at Abiomed through a period of significant expansion.She previously led the investor relations department at gene and cell therapy developer Bluebird Bio. Before entering the healthcare industry, Goldberg worked at Bank of America Merrill Lynch for a decade.

Regarding this appointment, Goldberg stated: "Medtronic improves patients' lives every day through concrete actions, and its product portfolio is highly attractive. I am eager to share the company's innovative progress with the outside world and contribute to such a company that is committed to enhancing human health."

Amid this personnel change, the former head of investor relations, Ryan Weispfenning, will transition to a new role, focusing on leading the investor relations function for MiniMed, which is set to spin off from Medtronic as an independent company.

Medtronic expects his experience to play a key role in the spin-off process of MiniMed. Weispfenning himself stated, "Having led Medtronic's investor relations efforts over the past decade, I am honored to now help MiniMed establish an independent investor relations function and communicate its long-term strategy and growth commitment as a standalone public company to investors."

To ensure continuity of work, Medtronic stated that Ryan Weispfenning will support the new director, Ingrid Goldberg, and her team for a period of time to ensure a smooth transition.